Maiwald Magazine

Press Coverage

24 Jun 2025 - Press Coverage

Maiwald Advises Royalty Pharma on $2 Billion Funding Agreement with Revolution Medicines

Maiwald acted as legal advisor to Royalty Pharma in connection with an innovative funding agreement totaling up to $2 billion with Revolution Medicines. The transaction includes up to $1.25 billion in synthe...

15 Apr 2025 - Press Coverage

Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics

Cyprumed GmbH and Merck & Co., Inc. have entered a Non-Exclusive License and Option Agreement to develop oral formulations of peptides using Cyprumed’s drug delivery technology. MSD gains global non-exclusive rights...

2 Apr 2025 - Press Coverage

Managing IP names Maiwald one of the leading IP law firms in Germany

The market analysis by Managing IP and the IP STARS ranking 2024 confirm this: The German market for intellectual property remains dynamic and highly competitive. Especially in the field of patent law, numerous law firms were able to maintain and expand their leading positio...

Maiwald in the press

Publications

11 Jun 2025 - Publication

Managing IP Awards interview: Maiwald
ManagingIP June 10, 2025

In their recent feature with Managing IP, senior representatives from Maiwald – Dr. Anja Fux, Dr. Derk Vos, Heike Roeder-Hitschke, Dr. Nils Braun and Martina Boidol...

30 Apr 2025 - Publication

Safe Harbor Provision in European Patent LawThe Research & Bolar Exemptions, AIPLA Chemical Practice Chronicles Newsletter, Volume 13 Issue 1 2025

This article covers the most recent developments regarding the European Research Exemption, which permits the use of patented inventions for research purposes, as well as the ...

30 Apr 2025 - Publication

The ‘long-arm’ of the Unified Patent Court – New developments in European cross-border patent litigation, AIPLA Chemical Practice Chronicles Newsletter, Volume 13 Issue 1 2025

The jurisdictional reach of the Unified Patent Court (UPC) was a widely and controversially discussed topic from the outset. Some practitioners took the view that the UPC also...

All publications

Events

Wed.

16 Jul 2025 |Upcoming|External Events

Maiwald at the Industrial Property Rights Day in Stuttgart

On 16 July 2025, Maiwald will be taking part in the Industrial Property Rights Day at the Haus der Wirtschaft in Stuttgart. The all-day event offers practical insights into current topics relating to patents, trade marks and design - with specialist presentations, expert forums and an exhibition of innovative IP tools. O...

Sun.

28 Sep 2025 |Upcoming|External Events

Maiwald at TMAP 2025 in Berlin, September 28-30, 2025

We are pleased to participate in the INTA Trademark Administrators & Practitioners (TMAP) Meeting 2025 in Berlin. This prestigious event brings together trademark administrators, patent paralegals, young professionals and attorneys working in the field of trademark law.The diverse conference program will cover current developments in trademark law and practical top...

Mon.

13 Oct 2025 |Upcoming

Maiwald Platinum Partner at the 2025 Life Sciences Strategy Summit on IP & Exclusivity

We are pleased to announce that Maiwald Intellectual Property will participate as a Platinum Partner at the upcoming Life Sciences Strategy Summit on IP & Exclusivity, taking place in the Infinity Hotel & Conference Resort Munich from 13–15 October 2025.

Wed.

21 May 2025 |Past Event|External Events

C5’s 18th Annual Forum on “Pharma & Biotech Patent Litigation in Europe” in Amsterdam

We are pleased that Dr. Eva Ehlich was an expert at the 18th C5 Communications Forum on “Pharma & Biotech Patent Litigation in Europe” in Amsterdam. Eva gave a presentation on “Plausibility and Post-Publication Evidence in Inventive Step ...

All events

News and Releases

Maiwald Blog

Turn one into several – what Rule 80 EPC says about using several independent claims to defend one independent claim

EPO Board of Appeal 3.3.04 is setting the right standard for acknowledging novelty of non-medical use claims (T 1913/21)

EPO revokes Roche’s Patent on combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer that was supported by results of Phase III AURELIA clinical trial

Press Coverage

Maiwald Advises Royalty Pharma on $2 Billion Funding Agreement with Revolution Medicines

Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics

Managing IP names Maiwald one of the leading IP law firms in Germany

Staff News

Maiwald appoints Alexander Feil, Dr. Johannes Scholz and Dr. Fabian Wiescher as Counsel

Dr. Patrick Heeger and Dr. Andre Mähringer sworn in as German patent attorneys

Maiwald congratulates Dr. Anna Closs on passing the exam

Publications

Managing IP Awards interview: Maiwald
ManagingIP June 10, 2025

Safe Harbor Provision in European Patent LawThe Research & Bolar Exemptions, AIPLA Chemical Practice Chronicles Newsletter, Volume 13 Issue 1 2025

The ‘long-arm’ of the Unified Patent Court – New developments in European cross-border patent litigation, AIPLA Chemical Practice Chronicles Newsletter, Volume 13 Issue 1 2025

Awards

2025 IP Stars Patent Rankings in the categories “Patent Prosecution” and “Patent Disputes” revealed

Dr. Marco Stief honoured as Thought Leader Germany, Lexology Index 2025

Leaders League Ranking Germany 2025

Events

Maiwald at the Industrial Property Rights Day in Stuttgart

Maiwald at TMAP 2025 in Berlin, September 28-30, 2025

Maiwald Platinum Partner at the 2025 Life Sciences Strategy Summit on IP & Exclusivity

C5’s 18th Annual Forum on “Pharma & Biotech Patent Litigation in Europe” in Amsterdam